Literature DB >> 31164711

Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis.

Yanmin Zhao1,2,3, Jimin Shi1,2,3, Xiaoqing Li1,2,3, Jiasheng Wang4, Jie Sun1,2,3, Jianfeng Zhou5, He Huang6,7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31164711     DOI： 10.1038/s41409-019-0577-2

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  6 in total

1.  Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis.

Authors:  Romain Lévy; Mathieu Fusaro; Frédéric Guerin; Ahmed Chetouani; Despina Moshous; Alain Fischer; Geneviève de Saint Basile; Fernando E Sepulveda; Bénédicte Neven
Journal:  Blood Adv       Date:  2020-04-14

2.  Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.

Authors:  Scott R Goldsmith; Sana Saif Ur Rehman; Cara L Shirai; Kiran Vij; John F DiPersio
Journal:  Blood Adv       Date:  2019-12-10

3.  COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.

Authors:  Cirino Botta; Alessia Indrieri; Eugenio Garofalo; Flavia Biamonte; Andrea Bruni; Pino Pasqua; Francesco Cesario; Francesco Saverio Costanzo; Federico Longhini; Francesco Mendicino
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

Review 4.  Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies.

Authors:  Halil Yildiz; Sarah Bailly; Eric Van Den Neste; Jean Cyr Yombi
Journal:  Ther Clin Risk Manag       Date:  2021-04-14       Impact factor: 2.423

Review 5.  Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.

Authors:  Camille Keenan; Kim E Nichols; Sabrin Albeituni
Journal:  Front Immunol       Date:  2021-02-16       Impact factor: 7.561

Review 6.  The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature.

Authors:  Alice Wang; Katelyn Singh; Wael Ibrahim; Brett King; William Damsky
Journal:  Yale J Biol Med       Date:  2020-03-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.